Silo Pharma Inc. (NASDAQ: SILO)

Silo Pharma Inc. (NASDAQ: SILO) is a cutting-edge biopharmaceutical company focused on developing novel therapeutics to address underserved medical conditions, particularly in the fields of stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company is at the forefront of integrating conventional drug therapies with innovative psychedelic treatments, utilizing advanced formulations and drug delivery systems to enhance efficacy and patient outcomes. Through strategic collaborations with universities and independent laboratories, Silo Pharma is pioneering a new era in biopharmaceutical research and development.

The company’s lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders. This novel approach leverages intranasal delivery to provide rapid relief by directly accessing the central nervous system. Additionally, Silo Pharma is developing SP-26, a time-release ketamine-loaded implant aimed at providing long-term pain relief for fibromyalgia and other chronic pain conditions. These innovative treatments represent significant advancements in addressing complex and often intractable symptoms associated with these conditions.

Beyond its lead candidates, Silo Pharma is also advancing two promising preclinical programs: SPC-14, an intranasal compound for treating Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). These programs underscore the company’s commitment to addressing significant unmet needs in the CNS therapeutic landscape. As Silo Pharma continues to develop its diverse pipeline, it aims to make meaningful contributions to psychiatry, pain management, and neurodegenerative diseases, offering new found hope to patients and significant potential value to investors.

SPC-15

Silo Pharma’s lead candidate, SPC-15, is an innovative intranasal treatment designed to address PTSD and other stress-induced anxiety disorders by targeting serotonin 4 (5-HT4) receptors. The treatment uses a cutting-edge, microchip-based spray system developed by Resyca BV, a joint venture between Bespak Group and Medspray Pharma BV. This advanced delivery method allows for direct nose-to-brain drug dispersion, bypassing the blood-brain barrier, potentially resulting in a faster onset of therapeutic benefits and optimized safety for patients. Silo Pharma’s collaboration with Columbia University supports ongoing preclinical studies and the development of SPC-15, with the potential to utilize the FDA’s streamlined 505(b)(2) regulatory pathway for expedited drug approval.

Currently, Silo Pharma is conducting GLP-compliant pharmacokinetic and pharmacodynamic studies for SPC-15, having submitted a pre-IND briefing package to the U.S. Food and Drug Administration (FDA). These studies are critical steps toward the submission of an IND application, with the goal of initiating the first human clinical trials. The company’s exclusive license with Medspray Pharma BV grants it the rights to further develop, manufacture, and commercialize SPC-15 worldwide, positioning Silo Pharma to potentially bring this novel PTSD treatment to market and address a critical unmet medical need.

Market Opportunity

Silo Pharma’s market opportunity is substantial, particularly in the emerging field of psychedelic therapeutics and advanced drug delivery systems, which are gaining increasing attention from both the medical community and investors. The company’s focus on developing treatments for conditions like PTSD, chronic pain, and CNS disorders places it in a unique position to capitalize on the growing demand for innovative therapies that address challenging unmet medical needs. With vastly increased recognition, the global market for PTSD treatments projected to grow significantly in the coming years. Silo Pharma’s timely development of SPC-15 and its pipeline of novel treatments aim to capture a considerable share of this expanding market.

From an investment perspective, Silo Pharma’s partnerships with leading research institutions and technology providers, such as Resyca BV, enhance its ability to bring advanced therapeutics to market efficiently. The company’s strategic use of the FDA’s 505(b)(2) regulatory pathway could potentially expedite the approval process for its lead candidate, SPC-15, reducing time to market and associated costs. As the biopharmaceutical sector continues to see increased interest in innovative drug delivery systems and psychedelic therapies, Silo Pharma is well-positioned to attract investment and achieve significant growth, making it a promising prospect for investors looking to enter this dynamic and rapidly evolving market.

Leadership Team

Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc., bringing nearly 20 years of experience in structuring and trading financial instruments. Prior to founding Silo Pharma, Mr. Weisblum was a private investor and advisor to several portfolio companies, with a focus on in-licensing therapeutic assets and assisting in their development. He holds a B.A. from the University of Hartford’s Barney School of Business and is actively involved in his community.

Dr. Kevin Muñoz, a member of Silo Pharma’s Board of Directors since October 2020, is an experienced healthcare professional currently teaching Biomedical Sciences and medical intervention at Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation, where he focused on enhancing patient satisfaction and managing office operations. Dr. Muñoz holds a Bachelor of Science from the University of Michigan, graduating with distinction, and earned his Doctor of Medicine from Xavier University School of Medicine in Aruba.